H2Mab-19 recognized endogenous HER2 in a breast cancer cell line, BT-474, which is HER2-positive (18), but did not react with a breast cancer cell line, MDA-MB-468, which is HER2-negative (18) (Fig. 1A). This evidence concerns the gene ERBB2 and breast cancer.